An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific cholesterol-raising conditions.

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about ...

It’s time to step up the opposition to designer babies, says Marcy Darnovsky of the Center for Genetics and Society ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

The gene therapy regimen seems to be working wonders, including restoring nearly all hearing to a seven-year-old patient ...

The Canadian government is currently considering approving the entry of gene-edited pigs into the food system.

Citrus greening is a disease with no known cure that has infected nearly every citrus grove. It first cropped up 20 years ago. There's still no cure.

Analysts have also weighed in on stock throughout the month. Recent analyst calls on the stock include: Needham analyst Gil ...

Additionally, investors may have begun repositioning portfolios ahead of the release of second-quarter earnings results.

CZI and the IGI announce the funding of the Center for Pediatric CRISPR Cures to use CRISPR-based editing technology to advance cures.